BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 27670423)

  • 1. High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia.
    Chiang MY; Wang Q; Gormley AC; Stein SJ; Xu L; Shestova O; Aster JC; Pear WS
    Blood; 2016 Nov; 128(18):2229-2240. PubMed ID: 27670423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia.
    Sanchez-Martin M; Ferrando A
    Blood; 2017 Mar; 129(9):1124-1133. PubMed ID: 28115368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
    Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
    J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells.
    Hales EC; Orr SM; Larson Gedman A; Taub JW; Matherly LH
    J Biol Chem; 2013 Aug; 288(31):22836-48. PubMed ID: 23788636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1.
    Matsushita K; Kitamura K; Rahmutulla B; Tanaka N; Ishige T; Satoh M; Hoshino T; Miyagi S; Mori T; Itoga S; Shimada H; Tomonaga T; Kito M; Nakajima-Takagi Y; Kubo S; Nakaseko C; Hatano M; Miki T; Matsuo M; Fukuyo M; Kaneda A; Iwama A; Nomura F
    Oncotarget; 2015 Mar; 6(7):5102-17. PubMed ID: 25671302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.
    López-Nieva P; González-Sánchez L; Cobos-Fernández MÁ; Córdoba R; Santos J; Fernández-Piqueras J
    Oncologist; 2021 Feb; 26(2):e298-e305. PubMed ID: 33191568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia.
    Pajcini KV; Xu L; Shao L; Petrovic J; Palasiewicz K; Ohtani Y; Bailis W; Lee C; Wertheim GB; Mani R; Muthusamy N; Li Y; Meijerink JPP; Blacklow SC; Faryabi RB; Cherry S; Pear WS
    Sci Signal; 2017 Nov; 10(505):. PubMed ID: 29138297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL.
    Jeannet R; Mastio J; Macias-Garcia A; Oravecz A; Ashworth T; Geimer Le Lay AS; Jost B; Le Gras S; Ghysdael J; Gridley T; Honjo T; Radtke F; Aster JC; Chan S; Kastner P
    Blood; 2010 Dec; 116(25):5443-54. PubMed ID: 20829372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
    Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
    Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The common oncogenomic program of NOTCH1 and NOTCH3 signaling in T-cell acute lymphoblastic leukemia.
    Choi SH; Severson E; Pear WS; Liu XS; Aster JC; Blacklow SC
    PLoS One; 2017; 12(10):e0185762. PubMed ID: 29023469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convergence of the ZMIZ1 and NOTCH1 pathways at C-MYC in acute T lymphoblastic leukemias.
    Rakowski LA; Garagiola DD; Li CM; Decker M; Caruso S; Jones M; Kuick R; Cierpicki T; Maillard I; Chiang MY
    Cancer Res; 2013 Jan; 73(2):930-41. PubMed ID: 23161489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
    Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
    Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma.
    Weng AP; Millholland JM; Yashiro-Ohtani Y; Arcangeli ML; Lau A; Wai C; Del Bianco C; Rodriguez CG; Sai H; Tobias J; Li Y; Wolfe MS; Shachaf C; Felsher D; Blacklow SC; Pear WS; Aster JC
    Genes Dev; 2006 Aug; 20(15):2096-109. PubMed ID: 16847353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Murine Pten(-/-) T-ALL requires non-redundant PI3K/mTOR and DLL4/Notch1 signals for maintenance and γc/TCR signals for thymic exit.
    Hagenbeek TJ; Wu X; Choy L; Sanchez-Irizarry C; Seshagiri S; Stinson J; Siebel CW; Spits H
    Cancer Lett; 2014 May; 346(2):237-48. PubMed ID: 24384093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature.
    Efimenko E; Davé UP; Lebedeva IV; Shen Y; Sanchez-Quintero MJ; Diolaiti D; Kung A; Lannutti BJ; Chen J; Realubit R; Niatsetskaya Z; Ten V; Karan C; Chen X; Califano A; Diacovo TG
    Mol Cancer Ther; 2017 Oct; 16(10):2069-2082. PubMed ID: 28716817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
    Sanda T; Li X; Gutierrez A; Ahn Y; Neuberg DS; O'Neil J; Strack PR; Winter CG; Winter SS; Larson RS; von Boehmer H; Look AT
    Blood; 2010 Mar; 115(9):1735-45. PubMed ID: 20007543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FHL1C induces apoptosis in Notch1-dependent T-ALL cells through an interaction with RBP-J.
    Fu W; Wang K; Zhao JL; Yu HC; Li SZ; Lin Y; Liang L; Huang SY; Liang YM; Han H; Qin HY
    BMC Cancer; 2014 Jun; 14():463. PubMed ID: 24952875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-Catenin is required for T-cell leukemia initiation and MYC transcription downstream of Notch1.
    Gekas C; D'Altri T; Aligué R; González J; Espinosa L; Bigas A
    Leukemia; 2016 Oct; 30(10):2002-2010. PubMed ID: 27125305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.
    Aste-Amézaga M; Zhang N; Lineberger JE; Arnold BA; Toner TJ; Gu M; Huang L; Vitelli S; Vo KT; Haytko P; Zhao JZ; Baleydier F; L'Heureux S; Wang H; Gordon WR; Thoryk E; Andrawes MB; Tiyanont K; Stegmaier K; Roti G; Ross KN; Franlin LL; Wang H; Wang F; Chastain M; Bett AJ; Audoly LP; Aster JC; Blacklow SC; Huber HE
    PLoS One; 2010 Feb; 5(2):e9094. PubMed ID: 20161710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.